<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35238072</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>31</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1939-1676</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>36</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of veterinary internal medicine</Title>
          <ISOAbbreviation>J Vet Intern Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Incidence of hepatopathies in dogs administered zonisamide orally: A retrospective study of 384 cases.</ArticleTitle>
        <Pagination>
          <StartPage>576</StartPage>
          <EndPage>579</EndPage>
          <MedlinePgn>576-579</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/jvim.16398</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Acute hepatopathy secondary to administration of zonisamide has been reported in 2 dogs, but overall incidence of hepatopathy is unknown.</AbstractText>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To characterize the incidence of hepatopathy in dogs administered zonisamide PO.</AbstractText>
          <AbstractText Label="ANIMALS" NlmCategory="METHODS">Three hundred eighty-four dogs administered zonisamide PO.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Multicenter retrospective study. Medical records were searched for dogs prescribed zonisamide PO and which had follow-up for at least 3 months (acute exposure) and &gt;3 months (chronic exposure). Reported clinical signs, physical examination findings, and serum biochemical panels were reviewed for possible hepatotoxicosis. Serum alanine aminotransferase (ALT) and alkaline phosphatase (ALP) activity and albumin concentration were documented for all available cases.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Acute clinical hepatopathy was found in 2 of 384 treated dogs (0.52%, 95% confidence interval [CI], 0.06-1.9) after 13-16 days of zonisamide treatment. One additional dog had elevated serum ALT activity with no clinical signs. Of these 3 dogs, 2 recovered after administration of zonisamide was stopped, and 1 was euthanized because of liver failure. Of the 117 cases chronically administered zonisamide, 10 had an increase in ALP, 6 had an increase in ALT, and 1 had hypoalbuminemia. No clinical signs of liver disease were noted in dogs chronically treated with zonisamide (median, 20 months; range, 5-94 months).</AbstractText>
          <AbstractText Label="CONCLUSIONS AND CLINICAL IMPORTANCE" NlmCategory="CONCLUSIONS">Acute, potentially life-threatening hepatopathy associated with oral administration of zonisamide to dogs is estimated to occur in less than 1% of dogs and was observed in the first 3 weeks of treatment. Subclinical abnormalities in ALT and ALP activity were noted in &lt;10% of dogs during chronic administration of zonisamide, with no clinical signs of liver disease noted.</AbstractText>
          <CopyrightInformation>© 2022 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Smith</LastName>
            <ForeName>Tess K</ForeName>
            <Initials>TK</Initials>
            <AffiliationInfo>
              <Affiliation>University of Wisconsin - Madison, Madison, Wisconsin, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cameron</LastName>
            <ForeName>Starr</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0001-5009-2546</Identifier>
            <AffiliationInfo>
              <Affiliation>University of Wisconsin - Madison, Madison, Wisconsin, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Trepanier</LastName>
            <ForeName>Lauren A</ForeName>
            <Initials>LA</Initials>
            <Identifier Source="ORCID">0000-0001-8585-7350</Identifier>
            <AffiliationInfo>
              <Affiliation>University of Wisconsin - Madison, Madison, Wisconsin, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016448">Multicenter Study</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Vet Intern Med</MedlineTA>
        <NlmUniqueID>8708660</NlmUniqueID>
        <ISSNLinking>0891-6640</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>459384H98V</RegistryNumber>
          <NameOfSubstance UI="D000078305">Zonisamide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004283" MajorTopicYN="Y">Dog Diseases</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008107" MajorTopicYN="Y">Liver Diseases</DescriptorName>
          <QualifierName UI="Q000662" MajorTopicYN="N">veterinary</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000078305" MajorTopicYN="N">Zonisamide</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">adverse effects</Keyword>
        <Keyword MajorTopicYN="N">antiepileptic drug</Keyword>
        <Keyword MajorTopicYN="N">epilepsy</Keyword>
        <Keyword MajorTopicYN="N">seizures</Keyword>
      </KeywordList>
      <CoiStatement>Lauren A. Trepanier serves as Associate Editor for the Journal of Veterinary Internal Medicine. She was not involved in review of this manuscript. No other authors have a conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>3</Day>
          <Hour>5</Hour>
          <Minute>39</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35238072</ArticleId>
        <ArticleId IdType="pmc">PMC8965215</ArticleId>
        <ArticleId IdType="doi">10.1111/jvim.16398</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
de Luisa L, Platt S. Canine and Feline Epilepsy Diagnosis and Management. 1st ed.
CABI: Boston, MA. USA.
2014:414‐424.</Citation>
        </Reference>
        <Reference>
          <Citation>
Dewey CW, Guiliano R, Boothe DM, et al. Zonisamide therapy for refractory idiopathic epilepsy in dogs. J Am Anim Hosp Assoc. 2004;40(4):285‐291.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15238558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
von Klopmann T, Rambeck B, Tipold A. Prospective study of zonisamide therapy for refractory idiopathic epilepsy in dogs. J Small Anim Pract. 2007;48(3):134‐138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17355603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chung J, Hwang C, Chae J, et al. Zonisamide monotherapy for idiopathic epilepsy in dogs. N Z Vet J. 2012;60(6):357‐359.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22639873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schwartz M, Munana KR, Olby NJ. Possible drug‐induced hepatopathy in a dog receiving zonisamide monotherapy for treatment of cryptogenic epilepsy. J Vet Med Sci. 2011;73(11):1505‐1508.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21720107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Miller ML, Center SA, Randolph JF, Lepherd ML, Cautela MA, Dewey CW. Apparent acute idiosyncratic hepatic necrosis associated with zonisamide administration in a dog. J Vet Intern Med. 2011;25(5):1156‐1160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21985145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Walker R. Chronic toxicity of the anticonvulsant zonisamide in Beagle dogs. Fundam Appl Toxicol. 1988;11(2):333‐342.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3220211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Solter PF, Hoffman WE, Chambers MD, Schaeffer DJ, Kuhlenschmidt MS. Hepatic total 3 alpha‐hydroxy bile acids concentration and enzyme activities in prednisone. Am J Vet Res. 1994;55:1086‐1092.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7978647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gaskill CL, Miller LM, Mattoon JS, et al. Liver histopathology and liver and serum alanine aminotransferase and alkaline phosphatase activities in epileptic dogs receiving phenobarbital. Vet Pathol. 2005;42(2):147‐160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15753468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dayrell‐Hart B, Steinberg SA, VanWinkle TJ, Farnbach GC. Hepatotoxicity of phenobarbital in dogs: 18 cases (1985‐1989). J Am Vet Med Assoc. 1991;199(8):1060‐1066.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1748613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Müller PB, Taboada J, Hosgood G, et al. Effects of long‐term phenobarbital treatment on the liver in dogs. J Vet Intern Med. 2000;14(2):165‐171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7197517</ArticleId>
            <ArticleId IdType="pubmed">10772488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ahmed SN, Siddiqi ZA. Antiepileptic drugs and liver disease. Seizure. 2006;15(3):156‐164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16442314</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
